ALK and non-small cell lung carcinoma: In the phase-III Study ASCEND 4 comparing in first line ceritinib vs. chemotherapy (pemetrexed and cis- or carboplatin) in ALK+ NSCLC, 32% of patients had brain metastases at diagnosis.